{
  "data": {
    "indicator": {
      "slug": "share-of-priority-review-drug-approval-applications-treating-cancer-annual",
      "name": "Share of priority review drug approval applications treating cancer (annual)",
      "definition": "Percentage share of priority review drug approval applications targeting oncology indications.",
      "unit": "percent",
      "scale": "1",
      "default_unit": "percent",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "percent",
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2020-01-01",
        "period_label": "2020–2024",
        "value": 42.54,
        "scale": "1",
        "unit": "percent",
        "value_type": "actual",
        "statistic_id": "stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8",
        "url": "https://statorigin.org/stat/stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8",
        "source_org": "NMPA",
        "source": {
          "org": "National Medical Products Administration",
          "org_short_name": "NMPA",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "CN"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}